Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

144 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
First-line pyrotinib in advanced HER2-mutant non-small-cell lung cancer: a patient-centric phase 2 trial.
Liu SM, Tu HY, Wei XW, Yan HH, Dong XR, Cui JW, Zhou Z, Xu CR, Zheng MY, Li YS, Wang Z, Bai XY, Li AN, Sun YL, Huang J, Lin JX, Ke EE, Xu BF, Lu C, Du Y, Chen Y, Ma R, Wang BH, Cang SD, Wang BC, Chen HJ, Yang JJ, Li Y, Zhou Q, Wu YL. Liu SM, et al. Among authors: zheng my. Nat Med. 2023 Aug;29(8):2079-2086. doi: 10.1038/s41591-023-02461-x. Epub 2023 Jul 24. Nat Med. 2023. PMID: 37488286 Clinical Trial.
A comprehensive review of uncommon EGFR mutations in patients with non-small cell lung cancer.
Tu HY, Ke EE, Yang JJ, Sun YL, Yan HH, Zheng MY, Bai XY, Wang Z, Su J, Chen ZH, Zhang XC, Dong ZY, Wu SP, Jiang BY, Chen HJ, Wang BC, Xu CR, Zhou Q, Mei P, Luo DL, Zhong WZ, Yang XN, Wu YL. Tu HY, et al. Among authors: zheng my. Lung Cancer. 2017 Dec;114:96-102. doi: 10.1016/j.lungcan.2017.11.005. Epub 2017 Nov 7. Lung Cancer. 2017. PMID: 29173773 Review.
Genetic Profiling of Cell-Free DNA From Pleural Effusion in Advanced Lung Cancer as a Surrogate for Tumor Tissue and Revealed Additional Clinical Actionable Targets.
Tu HY, Li YS, Bai XY, Sun YL, Zheng MY, Ke EE, Liao RQ, Jiang BY, Lin JX, Huang J, Xu BF, Yang JJ, Zhang XC, Zhou Q, Wang BC, Chen HJ, Tong X, Yu R, Wu X, Zhu D, Wu YL. Tu HY, et al. Among authors: zheng my. Clin Lung Cancer. 2022 Mar;23(2):135-142. doi: 10.1016/j.cllc.2021.09.002. Epub 2021 Sep 20. Clin Lung Cancer. 2022. PMID: 34645582
A potential treatment option for transformed small-cell lung cancer on PD-L1 inhibitor-based combination therapy improved survival.
Zhang CY, Sun H, Su JW, Chen YQ, Zhang SL, Zheng MY, Li YF, Huang J, Zhang C, Tai ZX, Cai M, Zhang XC, Su J, Xu CR, Yan HH, Chen HJ, Wu YL, Yang JJ. Zhang CY, et al. Among authors: zheng my. Lung Cancer. 2023 Jan;175:68-78. doi: 10.1016/j.lungcan.2022.11.016. Epub 2022 Nov 25. Lung Cancer. 2023. PMID: 36473332 Free article.
Efficacy, safety and dose selection of AZD3759 in patients with untreated EGFR-mutated non-small-cell lung cancer and central nervous system metastases in China (CTONG1702-Arm 8): a multi-center, single-arm, phase 2 trial.
Maggie Liu SY, Dong XR, Wang Z, Du Y, Cui JW, Chu Q, Xu BF, Zheng MY, Deng JY, Lu C, Wei XW, Li YS, Zheng MM, Yang MY, Huang J, Li A, Bai XY, Sun YL, Xu CR, Wang BC, Chen HJ, Yang JJ, Yan HH, Zhong WZ, Zhou Q, Wu YL. Maggie Liu SY, et al. Among authors: zheng my. EClinicalMedicine. 2023 Sep 22;64:102238. doi: 10.1016/j.eclinm.2023.102238. eCollection 2023 Oct. EClinicalMedicine. 2023. PMID: 37781161 Free PMC article.
PD-L1 expression guidance on sintilimab versus pembrolizumab with or without platinum-doublet chemotherapy in untreated patients with advanced non-small cell lung cancer (CTONG1901): A phase 2, randomized, controlled trial.
Maggie Liu SY, Huang J, Deng JY, Xu CR, Yan HH, Yang MY, Li YS, Ke EE, Zheng MY, Wang Z, Lin JX, Gan B, Zhang XC, Chen HJ, Wang BC, Tu HY, Yang JJ, Zhong WZ, Li Y, Zhou Q, Wu YL. Maggie Liu SY, et al. Among authors: zheng my. Sci Bull (Beijing). 2024 Feb 26;69(4):535-543. doi: 10.1016/j.scib.2023.12.046. Epub 2023 Dec 26. Sci Bull (Beijing). 2024. PMID: 38185589 Free article. Clinical Trial.
144 results